SIHD Guidelines. Personalized Medicine: Applying Guidelines to the Individual Patient With SIHD.

Slides:

Advertisements

Similar presentations

Complex Medication Review Robert Hallworth Chair – Greater Manchester Non-Medical Prescribing Network Oldham Primary Care Trust.

Advertisements

Ranexa™ for Chronic Angina An Unmet Need

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

The ERICA Trial Peter H. Stone, MD, FACC, Nikolay A. Gratsiansky, MD, Alexey Blokhin, MD, I-Zu Huang, MD, Lixin Meng, MS, MPH, for the ERICA Investigators.

Pramlintide Advisory Committee July 26, 2001 Symlin ® Amylin Pharmaceuticals New Drug Application (21-332) Advisory Committee Meeting Bethesda, Maryland.

Arthur Stillman, M.D., Ph.D., PI Pamela Woodard, M.D., Study Co-chair Randomized Evaluation of Patients with Stable Angina Comparing Utilization of Diagnostic.

European guidelines on the management of stable coronary artery disease Key points & new position for Ivabradine and Trimetazidine ESC 2013 Montalescot.

CR-1 1 Ranolazine Benefit/Risk Jeremy N. Ruskin, MD, FACC.

Redefining Treatment Strategies for Optimal Medical Care in CAD COURAGE and MERLIN-TIMI 36.

BARI 2D Trial BARI 2D Trial Presented at the American Diabetes Association (ADA) Annual Scientific Sessions 2009 in New Orleans The Bypass Angioplasty.

Diabetes Mellitus 101 for Medical Professionals An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes: Stan Schwartz MD,FACP.

MENU ΣΤΕΦΑΝΙΑΙΑ ΝΟΣΟΣ ΣΕ ΔΙΑΒΗΤΙΚΟΥΣ ΚΑΙ ΗΛΙΚΙΩΜΕΝΟΥΣ.

New Guidelines for Myocardial Ischemia Management.

Efficacy of Ranolazine In Chronic Angina trial

Contemporary Management of Myocardial Ischemia

Search strategy and results Amir Kashani, et al. Circulation. 2006;114:

Ranolazine The mechanism of action of ranolazine has not been determined, but it may be related to reduction in calcium overload in ischemic myocytes.

Adjuvant Ranolazine for Patients With Incomplete Revascularization

Evaluation of Ranolazine in Patients with Type 2 Diabetes Mellitus

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

EMPHASIS-HF Extended Follow-up

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Diabetes and Dyslipidemia

A CASE CHALLENGE IN HFrEF:

Dual Goals for the Management of Stable Ischemic Heart Disease (SIHD)

From the 2015 Conferences to the Clinic

The Latest Data on Oral Prostacyclin Therapy in PAH

New Perspectives in AF and PCI: Implications for the Practicing Physician.

Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum

Working as a Team for Improved Patient Outcomes in Type 2 Diabetes

Examining CV Effects of Basal Insulin Therapy

All About PAH:.

What Has Been Tried and What Is True?

Section I: RAS manipulation C. Update on clinical trials in CAD

Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?

How and When to Decide on Revascularization in Stable Ischemic Heart Disease.

Goals. Achieving HbA1c Goals: Applying Guidelines to Intensify Therapy in Patients With Diabetes.

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Recurrent Angina: New Tools for an Old Problem

Antiplatelet Therapy and Secondary Prevention

Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.

Statins and New-Onset Diabetes REAL Updates and Clinical Implications

Diabetes Increases Risk of CVD

Need to Know! Screening and Diagnosis of Kidney Disease in Diabetes

Case Study. Managing Medication and Adherence in SIHD: Partnering With the Patient to Improve Care.

AF and PCI in Practice.

Antithrombotic Protection in CAD and HF

Section 9: Continuum of care: Summary and timeline

Using Heart Rate as a Biomarker in Clinical Practice.

Tools to Address Adherence Issues in Patients With SIHD

The Primary Care Guide to New CGM Devices and the AGP

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Ranolazine in Microvascular Dysfunction

Typical Patient Presentation

How to Optimize Cholesterol Management in High-Risk CV Patients

Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

The Challenge of AF and PCI: Practical Strategies to Improve Outcomes

Patient Stories in PAH: Sequential Therapy in a FC II Patient

Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum

AMD Therapy: Where Are We Now and Where Are We Going?

Statin Selection in Patients With Pre-Diabetes: Case Considerations

A: Mean wall motion score index (95% CI) in patients with first myocardial infarction segregated by Hp type. A: Mean wall motion score index (95% CI) in.

RAASi Enabling in the Modern Era

Fresh perspectives ON BASAL Insulins in diabetes care

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Translating Data From Trial to Practice

Presentation transcript:

Personalized Medicine: Applying Guidelines to the Individual Patient With SIHD

SIHD Guidelines

Case 1: Patient With No Known CAD

Getting a Good History

SIHD Diagnostic Algorithm

Case 1: Patient With No Known CAD

Revascularization to Improve Survival

SIHD Guidelines: Smoking Cessation

SIHD Guidelines: Informed Patients

SIHD Guidelines: Antianginal Therapy

Post hoc Analysis of CARISA: Reduction in Angina Episodes by Diabetes Status

TERISA: Study Design

TERISA: Results

TERISA: Subgroup Analyses of Primary End Point of Weekly Angina Frequency

TERISA: Exploratory Analysis – HbA1c

Post hoc Analysis of CARISA: Reduction in HbA1C by Ranolazine Dose

Abbreviations